Literature DB >> 25517955

Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series.

Jane C Morrison1, Luis Z Blanco, Russell Vang, Brigitte M Ronnett.   

Abstract

A precursor for invasive ovarian/pelvic high-grade serous carcinoma, termed serous tubal intraepithelial carcinoma (STIC), has been identified and characterized through careful analysis of the fallopian tubes in both prophylactic salpingo-oophorectomy specimens obtained from women with either a family history of breast and/or ovarian cancer or germline mutations of BRCA1 and BRCA2 and in cases of pelvic high-grade serous carcinoma. Data on incidental STICs and clinically occult microscopic invasive high-grade serous carcinomas are limited. We analyzed the clinicopathologic features of 22 cases, including 15 pure STICs and 7 STICs associated with microscopic invasive high-grade serous carcinomas, identified incidentally in fallopian tubes removed for nonprophylactic indications. Patient age ranged from 39 to 79 years (mean: 62.7; median: 61), with only 1 patient under the age of 50. No patients were known to carry BRCA1 or BRCA2 mutations. Of the 12 pure STICs for which the location in the fallopian tube could be established, 9 were in the fimbriated portion, 1 was at the junction of the fimbria and infundibulum, and 2 were in the nonfimbriated tube. Of the 7 STICs with associated invasive high-grade serous carcinoma, 3 were located in the fimbriated portion, 2 were at the junction of the fimbria and infundibulum, and 2 were in the nonfimbriated tube. The invasive components were in the fallopian tube in 6 cases, 4 in subepithelial stroma of tubal mucosa, and 2 as an intramucosal (exophytic) luminal lesion without invasion of underlying subepithelial stroma (size range: 1 to 4 mm). The remaining case had a microscopic focus of high-grade serous carcinoma within the ipsilateral ovary (1.3 mm cortical focus) identified only on deeper sections, without an associated invasive component in the fallopian tube. The preferential finding of atypical epithelium with the cytologic features of high-grade serous carcinoma, namely STIC, in the fallopian tubes rather than the ovaries as an incidental (clinically occult) microscopic lesion in the absence of widespread pelvic carcinoma provides further evidence that STIC is the earliest form of pelvic high-grade serous carcinoma and that the fallopian tube is the site of origin. This study demonstrates the potential for complete examination of the fallopian tubes and ovaries to identify STICs and early invasive serous carcinomas that might be more amenable to the earliest intervention and potential cure.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25517955     DOI: 10.1097/PAS.0000000000000352

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  22 in total

1.  Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study.

Authors:  L Minig; S Cabrera; R Oliver; A Couso; M J Rubio; S Iacoponi; M B Martin-Salamanca; S Carballo-Rastrilla; J M Cádenas-Rebollo; A García-Garcia; B Gil-Ibáñez; M J Juan-Fita; M G Patrono
Journal:  Clin Transl Oncol       Date:  2018-04-05       Impact factor: 3.405

Review 2.  Preclinical Models of Ovarian Cancer: Pathogenesis, Problems, and Implications for Prevention.

Authors:  Anthony N Karnezis; Kathleen R Cho
Journal:  Clin Obstet Gynecol       Date:  2017-12       Impact factor: 2.190

3.  Extrauterine high-grade serous carcinomas with bilateral adnexal involvement as the only two disease sites are clonal based on tp53 sequencing results: implications for biology, classification, and staging.

Authors:  Naveena Singh; Asma Faruqi; Friedrich Kommoss; W Glenn McCluggage; Giorgia Trevisan; Janine Senz; Amy Lum; C Blake Gilks; Michael Anglesio
Journal:  Mod Pathol       Date:  2017-11-17       Impact factor: 7.842

Review 4.  A guided tour of selected issues pertaining to metastatic carcinomas involving or originating from the gynecologic tract.

Authors:  Robert A Soslow; Rajmohan Murali
Journal:  Semin Diagn Pathol       Date:  2017-11-20       Impact factor: 3.464

Review 5.  The disparate origins of ovarian cancers: pathogenesis and prevention strategies.

Authors:  Anthony N Karnezis; Kathleen R Cho; C Blake Gilks; Celeste Leigh Pearce; David G Huntsman
Journal:  Nat Rev Cancer       Date:  2016-11-25       Impact factor: 60.716

Review 6.  The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Am J Pathol       Date:  2016-04       Impact factor: 4.307

Review 7.  Serous tubal intraepithelial neoplasia: the concept and its application.

Authors:  Emily E K Meserve; Jan Brouwer; Christopher P Crum
Journal:  Mod Pathol       Date:  2017-01-20       Impact factor: 7.842

Review 8.  Reframing How Physical Activity Reduces The Incidence of Clinically-Diagnosed Cancers: Appraising Exercise-Induced Immuno-Modulation As An Integral Mechanism.

Authors:  Annabelle Emery; Sally Moore; James E Turner; John P Campbell
Journal:  Front Oncol       Date:  2022-03-14       Impact factor: 6.244

9.  Increase of fallopian tube and decrease of ovarian carcinoma: fact or fake?

Authors:  Anne Kathrin Höhn; Sabine Klagges; Albrecht Gläser; Sabine Taubenheim; Nadja Dornhöfer; Jens Einenkel; Grit Gesine Ruth Hiller; Christine E Brambs; Lars-Christian Horn
Journal:  J Cancer Res Clin Oncol       Date:  2020-09-11       Impact factor: 4.553

10.  TP53 variants in p53 signatures and the clonality of STICs in RRSO samples.

Authors:  Tomoko Akahane; Kenta Masuda; Akira Hirasawa; Yusuke Kobayashi; Arisa Ueki; Miho Kawaida; Kumiko Misu; Kohei Nakamura; Shimpei Nagai; Tatsuyuki Chiyoda; Wataru Yamagami; Shigenori Hayashi; Fumio Kataoka; Kouji Banno; Kokichi Sugano; Hajime Okita; Kenjiro Kosaki; Hiroshi Nishihara; Daisuke Aoki
Journal:  J Gynecol Oncol       Date:  2022-03-21       Impact factor: 4.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.